Fear of a nuclear meltdown in Japan put the spotlight on Osiris (NASDAQ:OSIR) who is developing treatments for radiation poisoning.
Japan’s nuclear drama raises concerns about the US readiness in the event of a disaster such as an earthquake or a terrorist attack.
The Bottom Line: Conventional wisdom on Wall Street suggests that tragedies that incite panicky buys or selloffs in share pricing represent opportunity for pro-active investors. However, OSIR Prochymal is still awaiting regulatory approval. But, an excellent post (3/14/11) by MD Becker (https://seekingalpha.com/article/258121-earthquake-highlights-opportunity-for-treating-radiation-sickness highlights this visibility effect. Osiris (OSIR) is developing Prochymal for the treatment and prevention of acute radiation syndrome, a condition that has no cure. There are no treatment or prevention products approved in the US. The stock still dropped from $6.50 (3/14) to $6.38 on 3/ 15/11 and opened on 3/16/11 at $6.18 down -$0.20 or -3.13%.